LF10 + LDD01 + LP01™ + LS03 + ST10
Blend
On this page
Neurology
Amyotrophic lateral sclerosis (ALS)
Functionality
Supports gut microbiota of patients with ALS
Dosage / Clinical Study
1, 2) LF10 4 billion CFU + LDD01 2 billion CFU + LP01 2 billion CFU + LS03 2 billion CFU + ST10 5 billion CFU
Available Formats
Blend
Finished dosage form
Scientific Support
Clinical studies
1) Mazzini L. et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. 2018 Nov/Dec;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S68-S70. DOI: 10.1097/MCG.0000000000001042
2) Di Gioia et al. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis. BMC Med 2020 Jun 17;18(1):153. DOI: 10.1186/s12916-020-01607-9
